FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced the successful completion of the previously announced spin-off of BD's Biosciences & ...
Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-volume testing in regulated applications Announces ...
Waters Corporation has completed the previously announced combination with the biosciences & diagnostic solutions businesses of Becton, Dickinson and Company (BD). The transaction forms a global life ...
Eye redness was not a commonly reported side effect in clinical trials of YUVEZZI. In BRIO I and BRIO II the reports of adverse events of ocular hyperemia (eye redness) were low. 1,2 In BRIO II, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results